CliffBio
small molecule

MAYZENT

SIPONIMOD

Loss of exclusivityApril 2036latest FDA-listed patent expiry
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameMAYZENT
Active ingredientSIPONIMOD
StrengthEQ 1MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2021
Marketing statusRX

Listed patents

PatentExpiresType
12533340April 2036use U-4407
11944602April 2036use U-3889
12071402January 2032product
8492441November 2030use U-2511
7939519August 2028substance, product

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MAYZENT patent cliff — loss of exclusivity April 2036 | CliffBio